COULD GROWTH DIFFERENTIATION FACTOR-15 BE A NEW INFLAMMATORY PATHWAY IN PSORIASIS VULGARIS?

Year 2022, , 603 - 609, 27.12.2022

Selma Korkmaz , Fevziye Burcu Şirin , Havva Hilal Ayvaz , İjlal Erturan , Mehmet Yıldırım

https://doi.org/10.17343/sdutfd.1172484

Abstract

Objective
Psoriasis vulgaris is a chronic inflammatory disease,
in which T cells play an important role in the
etiopathogenesis and inflammatory mechanisms.
Growth differentiation factor (GDF) 15 is a member
of the transforming growth factor beta superfamily
(TGF-ß), which increases with inflammation and has
various cell regulatory functions. In this study; it was
aimed to evaluate the relationship between serum
GDF-15 level and tumor necrosis factor alpha (TNF-α),
which is thought to have a role in the etiopathogenesis
of the disease, and other metabolic parameters.
Material and Method
Forty-one patients with psoriasis vulgaris and
41 healthy controls were included in the study.
Dermatological examination of all patients was
performed and the psoriasis area severity index
(PASI) score was calculated. Height and weight
measurements, systolic and diastolic blood
pressures, waist and hip circumferences, lipid
profiles, and biochemical parameters of the patients
were evaluated. Serum GDF-15 and TNF-α levels
were measured by the ELISA method.
Results
There was no significant difference between the
patient and control groups in terms of age, gender, lipid
profiles, biochemical parameters and high-sensitivity
C-reactive protein (hs-CRP) levels. Serum GDF-15
and TNF-α levels were found to be significantly higher
in the patient group compared to the control group
(p<0.001 and p=0.015). A positive correlation was
found between GDF-15 and TNF-α levels (r=0.455,
p=0.04).
Conclusion
We think that GDF-15 may have a role in psoriasis,
especially in the inflammatory pathway associated
with TNF-α.

Keywords

Psoriasis, inflamation, GDF15, comorbidity

BÜYÜME FARKLILAŞMA FAKTÖRÜ-15 PSORİASİS VULGARİSTE YENİ BİR İNFLAMATUVAR YOLAK OLABİLİR Mİ?

Abstract

Amaç
Psoriasis vulgaris kronik inflamatuvar bir hastalık olup,
etyopatogenezde T hücrelerin önemli rol oynadığı inflamatuvar
mekanizmalar rol almaktadır. Son yıllarda
psoriasisin sadece deriye sınırlı olmayıp aynı zamanda
bazı komorbiditeler ile ilişkili olduğu gösterilmiştir.
Büyüme farklılaşma faktörü-15 (GDF-15), dönüştürücü
büyüme faktörü beta süper ailesinin (TGF-ß) bir
üyesidir ve inflamasyonla artmaktadır. Bu çalışmada;
serum GDF-15 düzeyi ve bunun hastalığın etyopatogenezinde
rolü olduğu düşünülen tümör nekrozis
faktör alfa (TNF-α) ve diğer metabolik parametrelerle
arasındaki ilişkinin değerlendirilmesi amaçlandı.
Gereç ve Yöntem
Çalışmaya 41 psoriasis vulgarisli hasta ve 41 sağlıklı
kontrol dahil edildi. Tüm katılımcıların dermatolojik
muayenesi yapıldı ve psoriasis alan ve şiddet indeksi
(PAŞİ) skoru hesaplandı. Tüm katılımcıların boy,
kilo ölçümleri, sistolik ve diastolik kan basınçları, bel
ve kalça çevreleri, lipit profilleri, biyokimyasal parametreleri
değerlendirildi. Serum GDF-15 ve TNF-α
düzeyleri ELİSA yöntemi ile ölçüldü.
Bulgular
Hasta ve kontrol grubu arasında yaş, cinsiyet, lipit
profilleri, biyokimyasal parametreler ve yüksek-sensitif
C-reaktif protein (hs-CRP) düzeyleri açısından
anlamlı fark gözlenmedi. Hasta grubunda kontrol grubuna
kıyasla serum GDF-15 ve TNF-α düzeyleri anlamlı
derecede yüksek bulundu (p<0.001 ve p=0.015).
GDF-15 ve TNF-α düzeyleri arasında pozitif korelasyon
saptandı (r=0.455, p=0.04).
Sonuç
GDF-15’in psoriasiste özellikle TNF-α ile ilişkili inflamatuvar
yolakta rolü olabileceğini düşünmekteyiz.

Keywords

Psoriasis, inflamasyon, GDF15, komorbidite

References

• 1. Ergun T. Etiopathogenesis of Psoriasis. Turkderm 2008; 42 Suppl 2: 18-22.
• 2. Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019 23;20(6):1475.
• 3. Takahashi H, Iızuka H. Psoriasis and metabolic syndrome. Journal of Dermatology 2012;39:212-8.
• 4. Yalcin MM, Altinova AE, Akturk M, Gulbahar O, Arslan E, Sendoğan DO et al. GDF-15 and Hepcidin Levels in Nonanemic Patients with Impaired Glucose Tolerance. J Diabetes Res. 2016;2016:1240843.
• 5. Adela R, Banerjee SK. GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective. J Diabetes Res. 2015; 2015: 490842.
• 6. Akbari H, Talaee R, Zaker ZF, Nikoueinejad H. Investigating the Correlation between Growth Differentiation Factor 15 Serum Level and Its Gene Expression with Psoriasis and Its Severity. Iran J Allergy Asthma Immunol. 2021;20(5):593-599.
• 7. Gülekon A, Adışen E. Psoriasis and Co-morbidities. Turkderm 2008;42:2:23-5.
• 8. Ku SH, Kwon WJ, Cho EB, Park EJ, Kim KH, Kim KJ. The Association between Psoriasis Area and Severity Index and Cardiovascular Risk Factor in Korean Psoriasis Patients. Ann Dermatol. 2016; 28: 360-3.
• 9. Shashaj B, Luciano R, Contoli B, Morino GS, Spreghini MR, Rustico C et al. Reference ranges of HOMA-IR in normal-weight and obese young Caucasians. Acta Diabetol. 2016;53(2):251- 60.
• 10. Desmedt S , Desmedt V , Leen De Vos LD, Delanghe JR, Reinhart Speeckaert R et al. Growth differentiation factor 15: A novel biomarker with high clinical potential. Crit Rev Clin Lab Sci.2019;56(5):333-350.
• 11. Ünal B, Alan S, Başsorgun Cİ, Karakaş AA, Elpek GÖ, Çiftçioğlu MA. The divergent roles of growth differentiation factor-15 (GDF-15) in benign and malignant skin pathologies. Arch Dermatol Res. 2015;307(7):551-7.
• 12. Tanrıkulu O, Sarıyıldız ME, Batmaz İ, Yazmalar L, Polat N, Kaplan İ et al. Serum GDF-15 level in rheumatoid arthritis: relationship with disease activity and subclinical atherosclerosis. Acta Reumatol Port. 2017;42(1):66-72.
• 13. Taşolar MK, Erfan G, Raimoğlu O, Albayrak H, Yanık ME. Role of GDF-15 as an inflammatory marker in patients with psoriasis vulgaris. Turkderm 2021;55:184-8.
• 14. Bao X, Borné Y, Muhammad IF, Nilsson J, Lind L,Malender O et al. Growth differentiation factor 15 is positively associated with incidence of diabetes mellitus: the Malmö Diet and Cancer-Cardiovascular Cohort. Diabetologia. 2019;62(1):78-86.
• 15. Pavo N, Wurm R, Neuhold S, Adlbrecht C, Vila G, Strunk G et al. GDF-15 Is Associated with Cancer Incidence in Patients with Type 2 Diabetes. Clin Chem. 2016;62(12):1612-1620.
• 16. Adela R, Banerjee SK. GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective. J Diabetes Res. 2015;2015:490842.
• 17. Echouffo-Tcheugui JB, Daya N, Matsushita K, Wang D, Ndumele CE, Rifai MA et al. Growth Differentiation Factor (GDF)- 15 and Cardiometabolic Outcomes among Older Adults: The Atherosclerosis Risk in Communities Study. Clin Chem. 2021;67(4):653-661.
• 18. Lukaszyk E, Lukaszyk M, Koc-Zorawska E, Bodzenta-Lukaszyk A, Malyszko J. GDF-15, iron, and inflammation in early chronic kidney disease among elderly patients. Int Urol Nephrol. 2016;48(6):839-44.
• 19. Yanaba K, Asano Y, Tada Y, Sugaya M, Kadono T, Sato S. Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity. Mod Rheumatol. 2012;22(5):668-75.
• 20. Wang X, Chen LL, Zhang Q. Increased Serum Level of Growth Differentiation Factor 15 (GDF-15) is Associated with Coronary Artery Disease. Cardiovasc Ther. 2016;34(3):138-43.
• 21. Sarıyıldız MA, Yazmalar L, Batmaz İ, Alpaycı M, Burkan YK, Sula B et al. Serum GDF-15 level in Behçet's disease: relationships between disease activity and clinical parameters Int J Dermatol . 2016;55(11):1289-1294.
• 22. Corre J, Hébraud H, Bourin P. Concise Review: Growth Differentiation Factor 15 in Pathology: A Clinical Role? Stem Cells Transl Med. 2013; 2(12): 946–952.
• 23. Kyriakou A , Patsatsi A, Vyzantiadis TA, Sotiriadis D. Serum Levels of TNF-α, IL-12/23p40, and IL-17 in Plaque Psoriasis and Their Correlation with Disease Severity. J Immunol Res. 2014; 2014: 467541.
• 24. Sereflican B, Goksugur N, Bugdayci G, Polat M, Parlak HA. Serum Visfatin, Adiponectin, and Tumor Necrosis Factor Alpha (TNF-α) Levels in Patients with Psoriasis and their Correlation with Disease Severity.Acta Dermatovenerol Croat. 2016;24(1):13-9.
• 25. Kalkan G. Comorbidities in psoriasis: The recognition of psoriasis as a systemic disease and current management. Turkderm- Turk Arch Dermatol Venereology 2017;51:71-7.
• 26. Niknezhad N, Haghighatkhah HA, Zargari O, Ghalamkarpour F, Younespour S, Niknejad N et al. High-sensitivity C-reactive protein as a biomarker in detecting subclinical atherosclerosis in psoriasis. Dermatol Ther. 2020;33(4):e13628.